

August 14, 2026

Consolidated Financial Results for the Six Months Ended June 30, 2026 (Under IFRS)

Company name: NIKKISO CO., LTD.
 Listing: Tokyo Stock Exchange
 Securities code: 6376
 URL: <https://www.nikkiso.com>
 Representative: Koichi Kato, Representative Director, President & CEO
 Inquiries: Masaharu Murakami, Director, Executive Officer, Head of Corporate Unit
 Telephone: +81-3-3443-3711
 Scheduled date to file semi-annual securities report: August 14, 2026
 Scheduled date to commence dividend payments: September 15, 2026
 Preparation of supplementary material on financial results: Yes
 Holding of financial results briefing: Yes

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the six months ended June 30, 2026 (from January 1, 2026 to June 30, 2026)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Profit before tax		Profit for the period	
Six months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
June 30, 2026	118,415	18.0	9,022	53.8	10,396	114.5	8,381	71.1
June 30, 2025	100,317	(2.3)	5,867	114.4	4,845	(31.8)	4,899	(17.4)

	Profit for the period attributable to owners of the Company		Total comprehensive income	
Six months ended	Millions of yen	%	Millions of yen	%
June 30, 2026	8,257	67.5	15,263	430.0
June 30, 2025	4,929	(17.2)	2,880	(83.2)

	Basic earnings per share	Diluted earnings per share
Six months ended	Yen	Yen
June 30, 2026	126.44	126.34
June 30, 2025	74.39	74.30

(2) Consolidated financial position

	Total assets	Total equity	Equity attributable to owners of the Company	Ratio of equity attributable to owners of the Company to total assets
As of	Millions of yen	Millions of yen	Millions of yen	%
June 30, 2026	374,083	173,912	171,946	46.0
December 31, 2025	358,129	160,228	158,176	44.2

2. Dividend Conditions

	Dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended December 31, 2025	-	18.00	-	22.00	40.00
Fiscal year ending December 31, 2026	-	30.00			
Fiscal year ending December 31, 2026 (Forecast)			-	30.00	60.00

Note: Revisions to the forecast of cash dividends most recently announced: Yes

3. Forecast of consolidated financial results for the fiscal year ending December 31, 2026 (from January 1, 2026 to December 31, 2026)

(Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Profit before tax		Profit for the period attributable to owners of the Company		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Fiscal year ending December 31, 2026	247,700	14.9	19,700	28.5	20,000	15.9	15,800	15.7	241.93

Note: Revisions to the earnings forecasts most recently announced: Yes

Please refer to “1. (3) Explanation of Consolidated Financial Forecasts and Other Forward-Looking Information” for more details.

* Notes

(1) Significant changes in the scope of consolidation during the period: None

(2) Changes in accounting policies and changes in accounting estimates

(i) Changes in accounting policies required by IFRS: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(3) Number of issued shares (ordinary shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of June 30, 2026	69,175,664 shares
As of December 31, 2025	69,175,664 shares

(ii) Number of treasury shares at the end of the period

As of June 30, 2026	3,822,482 shares
As of December 31, 2025	3,909,907 shares

(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

Six months ended June 30, 2026	65,307,408 shares
Six months ended June 30, 2025	66,255,889 shares

Note: The number of treasury shares at the end of the period and the number of treasury shares deducted for the calculation of the average number of shares during the period include the shares of the Company held by the Custody Bank of Japan, Ltd. (Trust E Account) as trust assets related to the Stock Benefit Trust (J-ESOP) system.

* Semi-annual financial results reports are exempt from review conducted by certified public accountants or an audit firm.

* Proper use of earnings forecasts, and other special matters

The forward-looking statements, including forecasts of financial results, contained in these materials are based on information currently available to the Company and on certain assumptions deemed to be reasonable. However, the Company makes no guarantee that these forecasts will be achieved. Actual financial results, etc. may differ substantially due to various factors.

1. Qualitative Information on Financial Results for Q2 FY2026

(1) Summary of Operating Results

(i) Overview of Financial Results

During this interim period, the business environment surrounding the Nikkiso Group (the “Group”) saw increased demand in the aircraft and energy-related markets. At the same time, the outlook remained uncertain, reflecting geopolitical risks, volatility in resource prices and foreign exchange rates, and uncertainty surrounding the procurement environment.

In the Industrial Business, capital investment demand in the LNG sector remained robust, driven by a review of U.S. climate change policies and the growing importance of energy security. In the next-generation energy field, including hydrogen and ammonia, regional differences have emerged in the pace of market formation and investment appetite, while investment priorities are shifting toward LNG. In addition, Nikkiso Clean Energy & Industrial Gases Group (“Nikkiso CE&IG”) is expanding into new business areas, such as the space industry. Under these circumstances, the Industrial Business as a whole recorded increases in both revenue and profit, driven by the steady execution of existing orders for machines and equipment related to industrial and liquid gas, together with the solid performance of the Industrial Pumps and Systems Business and Precision Equipment Business.

In the Aerospace Business, shipments of components for commercial aircraft increased, driven by the recovery in production activities and moves toward higher production volumes in the aircraft market. As a result, the Aerospace Business recorded increases in both revenue and profit.

In the hemodialysis market, a major market for the Medical Business, capital investment by domestic medical institutions remained subdued, while demand in Europe remained solid, and the market in Asia is expanding due to an increase in the number of patients and improvements in healthcare systems. In China, growth is still expected, although the competitive environment is changing as local manufacturers gain ground. Under these circumstances, revenue increased, led by overseas markets, mainly in Europe, although the domestic market remained weak. On the profit front, profit increased mainly due to higher revenue, notwithstanding an increase in product development and other expenses.

The impact of the heightened tensions in the Middle East on the Group’s business activities and financial results during the first half of FY2026 was limited.

Adjustments (corporate expenses, etc.) increased, mainly due to the absence of the ¥455 million gain on the transfer of the CRRT business that was recorded in the same period of the previous fiscal year.

As a result, the Group’s results for the first half of the fiscal year under review exceeded those of the same period of the previous fiscal year in terms of orders received, revenue, and operating profit. Furthermore, profit before tax and profit for the period attributable to owners of the Company increased significantly, largely reflecting the recording of a foreign exchange gain of 1,002 million yen, compared with a foreign exchange loss of 1,386 million yen in the same period of the previous year.

(unit: millions of yen)				
	Six months ended June 30, 2025	Six months ended June 30, 2026	Year over Year	
			Change	Rate of change
Orders received	105,494	133,862	+ 28,367	+ 26.9%
Revenue	100,317	118,415	+ 18,097	+ 18.0%
Operating profit	5,867	9,022	+ 3,155	+ 53.8%
Profit before tax	4,845	10,396	+ 5,550	+ 114.5%
Profit for the period attributable to owners of the Company	4,929	8,257	+ 3,328	+ 67.5%

(ii) Results by Segment

(unit: millions of yen)					
		Six months ended June 30, 2025	Six months ended June 30, 2026	Year over Year	
				Change	Rate of change
Orders received		105,494	133,862	+ 28,367	+ 26.9%
	Industrial Unit	67,409	93,739	+ 26,330	+ 39.1%
	Industrial Business	59,202	81,892	+ 22,689	+ 38.3%
	Aerospace Business	8,047	11,796	+ 3,749	+ 46.6%
	Medical Unit	38,209	40,144	+ 1,935	+ 5.1%
Revenue		100,317	118,415	+ 18,097	+ 18.0%
	Industrial Unit	61,847	78,088	+ 16,240	+ 26.3%
	Industrial Business	53,684	66,112	+ 12,427	+ 23.1%
	Aerospace Business	8,006	11,928	+ 3,921	+ 49.0%
	Medical Unit	38,586	40,346	+ 1,759	+ 4.6%
Segment profit		5,867	9,022	+ 3,155	+ 53.8%
	Industrial Unit	4,468	7,317	+ 2,848	+ 63.8%
	Industrial Business	4,881	6,377	+ 1,495	+ 30.6%
	Aerospace Business	(183)	966	+ 1,149	—
	Medical Unit	2,592	3,524	+ 931	+ 35.9%
Adjustments (corporate expenses, etc.)		(1,279)	(1,919)	(639)	—
Profit before tax		4,845	10,396	+ 5,550	+ 114.5%
Profit for the period attributable to owners of the Company		4,929	8,257	+ 3,328	+ 67.5%

*The total for the Industrial Unit includes the amount for the deep ultraviolet LED Business.

*The amount for each segment is shown before elimination of intersegment transactions.

《Business Environment and Performance by Business Segment》

Business	Main Products	Business and order environment for the interim period of the fiscal year ending December 31, 2026	Overview of interim financial results for the fiscal year ending December 31, 2026
Industrial Business	Machines and Equipment Relating to Industrial Gas and Liquid Gas	- Capital investment demand in the LNG sector remained robust, with progress on liquefaction plants, import terminals and marine transportation projects in North America, Europe, and Asia. - In the next-generation energy field, including hydrogen and ammonia, regional differences have emerged in the pace of market development and investment appetite, while investment priorities are shifting toward LNG. - New business opportunities are expanding within Nikkiso CE&IG, including business opportunities in the space industry.	- Nikkiso CE&IG posted increases in both revenue and profit, supported by the steady execution of existing orders and the effect of the depreciation of the yen. - The Group continued technology and product development for low-carbon and decarbonization-related markets and continued strengthening the integrated global operating structure between Nikkiso CE&IG and the Japanese operations.
	Industrial Pumps and Systems	- Backed by firm demand, orders received remained solid.	- Increased profits mainly due to tighter control of selling, general, and administrative expenses, etc.
	Precision Equipment	- Orders received decreased slightly, reflecting the continued adjustment phase of capital investment in the electronic components market and intensifying competition in the Chinese market.	- Both revenue and profit increased through the steady execution of existing orders.
Aerospace Business	Carbon Fiber Reinforced Plastic (CFRP) Moldings for Commercial Aircraft	- In the aircraft market, the recovery in production activities and moves toward higher production volumes gained momentum.	- Both revenue and profit increased, driven by higher shipments accompanying the market recovery.

Business	Main Products	Business and order environment for the interim period of the fiscal year ending December 31, 2026	Overview of interim financial results for the fiscal year ending December 31, 2026
Medical Business	Hemodialysis-related products	- In the domestic market, demand remained soft, as the number of hemodialysis patients is expected to decline over the medium to long term. - In the Chinese market, although capital investment demand is expanding, the competitive environment is changing as local manufacturers gain ground amid the progress of localization policies. - In the European market, demand remained firm, supported by the growing needs for high-performance and labor-saving solutions, as well as strong recognition of the Group's automated and high-performance models. - In Asian markets excluding China, demand continued to expand, backed by economic development and the enhancement of healthcare systems.	- Domestic revenue decreased, reflecting continued restraint in capital investment by medical institutions. - Overseas revenue increased, driven by sales growth in Europe and the weaker yen. - Profit increased mainly due to higher revenue, despite an increase in product development and other expenses. - In the U.S. market, sales of the new machine started in January 2026. As the next step, the Group continues to respond to the regulatory review process for the launch of a higher-end, multipurpose hemodialysis machine, aiming to expand the business through a broader product lineup.

(2) Qualitative Information on Consolidated Financial Position

Total assets at the end of this interim consolidated accounting period amounted to 374,083 million yen, an increase of 15,954 million yen compared to the end of the previous fiscal year. While “cash and cash equivalents” decreased, the main reasons for this were increases in “trade receivables and other receivables,” “inventories,” “other current assets,” and “long-term financial assets.”

Total liabilities at the end of this interim consolidated accounting period amounted to 200,170 million yen, an increase of 2,270 million yen compared to the end of the previous fiscal year. The main reason was the increase in borrowings.

Total equity at the end of this interim consolidated accounting period was 173,912 million yen, an increase of 13,683 million yen compared to the end of the previous fiscal year. The main factors were the increase in “retained earnings” and “other components of equity.”

(3) Explanation of Consolidated Financial Forecasts and Other Forward-Looking Information

Regarding the consolidated earnings forecast for the fiscal year ending December 31, 2026, the Group has revised the figures from those announced on February 13, 2026, taking into account the fact that the results for the interim period exceeded the initial forecast, as well as the current business environment and foreign exchange trends. For details of the revised earnings forecast, please refer to the “Notice Regarding Difference Between Financial Forecasts and Actual Results for the First Half of the Fiscal Year Ending December 31, 2026 and Revisions to Annual Financial Forecasts” published today.

2. Condensed Semi-Annual Consolidated Financial Statements and Major Notes

(1) Condensed semi-annual consolidated statement of financial position

(Millions of yen)

	As of December 31, 2025	As of June 30, 2026
Assets		
Current assets		
Cash and cash equivalents	44,584	37,983
Trade and other receivables	79,376	85,625
Other short-term financial assets	285	349
Inventories	60,752	63,137
Income taxes refund receivable	730	612
Other current assets	8,192	11,216
Subtotal	193,922	198,925
Assets held for sale	486	-
Total current assets	194,408	198,925
Non-current assets		
Property, plant and equipment	51,795	54,792
Goodwill and intangible assets	39,166	40,857
Right-of-use assets	28,396	28,873
Investments accounted for using equity method	5,928	6,469
Long-term financial assets	34,975	40,667
Deferred tax assets	2,526	2,633
Other non-current assets	931	863
Total non-current assets	163,720	175,157
Total assets	358,129	374,083

(Millions of yen)

	As of December 31, 2025	As of June 30, 2026
Liabilities and equity		
Liabilities		
Current liabilities		
Short-term borrowings	8,684	22,707
Trade and other payables	29,041	28,270
Lease liabilities	3,963	4,549
Other short-term financial liabilities	705	885
Income taxes payable	1,120	1,972
Provisions	1,634	1,668
Other current liabilities	42,476	38,423
Total current liabilities	87,625	98,477
Non-current liabilities		
Long-term borrowings	73,924	62,401
Lease liabilities	23,529	23,508
Other long-term financial liabilities	31	3
Net defined benefit liabilities	1,310	1,259
Income taxes payable	21	31
Provisions	891	1,097
Deferred tax liabilities	9,326	11,723
Other non-current liabilities	1,240	1,667
Total non-current liabilities	110,275	101,692
Total liabilities	197,900	200,170
Equity		
Share capital	6,544	6,544
Capital surplus	6,041	5,988
Treasury shares	(4,224)	(4,130)
Other components of equity	42,144	49,029
Retained earnings	107,670	114,515
Equity attributable to owners of the Company	158,176	171,946
Non-controlling interests	2,052	1,965
Total equity	160,228	173,912
Total liabilities and equity	358,129	374,083

(2) Condensed Semi-Annual Consolidated Statement of Profit or Loss and Condensed Semi-Annual Consolidated Statement of Comprehensive Income

Condensed semi-annual consolidated statement of profit or loss

(Millions of yen)

	Six months ended June 30, 2025 (From January 1, 2025 to June 30, 2025)	Six months ended June 30, 2026 (From January 1, 2026 to June 30, 2026)
Revenue	100,317	118,415
Cost of sales	(70,791)	(83,783)
Gross profit	29,526	34,631
Selling, general and administrative expenses	(24,640)	(26,020)
Other income	1,100	460
Other expenses	(119)	(49)
Operating profit	5,867	9,022
Financial income	787	1,682
Financial costs	(1,952)	(688)
Share of profit (loss) of associates and joint ventures accounted for using the equity method	143	379
Profit before tax	4,845	10,396
Income tax expense	53	(2,014)
Profit for the period	4,899	8,381
Profit for the period attributable to:		
Owners of the Company	4,929	8,257
Non-controlling interests	(29)	123
Profit for the period	4,899	8,381
Earnings per share		
Basic earnings per share (Yen)	74.39	126.44
Diluted earnings per share (Yen)	74.30	126.34

Condensed semi-annual consolidated statement of comprehensive income

(Millions of yen)

	Six months ended June 30, 2025 (From January 1, 2025 to June 30, 2025)	Six months ended June 30, 2026 (From January 1, 2026 to June 30, 2026)
Profit for the period	4,899	8,381
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Financial assets measured at fair value through other comprehensive income (loss)	4,454	3,211
Share of other comprehensive income (loss) of associates and joint ventures accounted for using the equity method	(3)	(2)
Total	4,450	3,209
Items that may be reclassified to profit or loss		
Exchange differences on translation of foreign operations	(6,364)	3,196
Gain (loss) on cash flow hedges	132	201
Share of other comprehensive income (loss) of associates and joint ventures accounted for using the equity method	(238)	274
Total	(6,470)	3,673
Other comprehensive income, net of tax	(2,019)	6,882
Total comprehensive income for the period	2,880	15,263
Total comprehensive income for the period attributable to:		
Owners of the Company	3,029	15,165
Non-controlling interests	(149)	98
Total comprehensive income for the period	2,880	15,263

(3) Condensed semi-annual consolidated statement of changes in equity

Six months ended June 30, 2025 (From January 1, 2025 to June 30, 2025)

(Millions of yen)

	Equity attributable to owners of the Company								
	Share capital	Capital surplus	Treasury shares	Other components of equity				Retained earnings	Total
				Financial assets measured at fair value through other comprehensive income	Exchange differences on translation of foreign operations	Profit (loss) in cash flow hedges	Total		
Balance at beginning of the period	6,544	6,016	(2,692)	6,846	27,350	92	34,289	95,912	140,070
Comprehensive income									
Profit for the period								4,929	4,929
Other comprehensive income				4,450	(6,501)	151	(1,899)		(1,899)
Total comprehensive income for the period	-	-	-	4,450	(6,501)	151	(1,899)	4,929	3,029
Transactions with owners									
Purchase of treasury shares			(0)						(0)
Disposal of treasury shares		8							8
Dividends								(993)	(993)
Share-based payment transactions		(4)	16						12
Transfer to retained earnings				(110)			(110)	110	-
Total	-	3	16	(110)	-	-	(110)	(883)	(973)
Balance at end of the period	6,544	6,020	(2,676)	11,186	20,848	244	32,279	99,958	142,126

	Non-controlling interests	Total
Balance at beginning of the period	1,935	142,005
Comprehensive income		
Profit for the period	(29)	4,899
Other comprehensive income	(120)	(2,019)
Total comprehensive income for the period	(149)	2,880
Transactions with owners		
Purchase of treasury shares		(0)
Disposal of treasury shares		8
Dividends	(127)	(1,121)
Share-based payment transactions		12
Transfer to retained earnings		-
Total	(127)	(1,100)
Balance at end of the period	1,658	143,784

Six months ended June 30, 2026 (From January 1, 2026 to June 30, 2026)

(Millions of yen)

	Equity attributable to owners of the Company								
	Share capital	Capital surplus	Treasury shares	Other components of equity				Retained earnings	Total
				Financial assets measured at fair value through other comprehensive income	Exchange differences on translation of foreign operations	Profit (loss) in cash flow hedges	Total		
Balance at beginning of the period	6,544	6,041	(4,224)	13,636	27,977	530	42,144	107,670	158,176
Comprehensive income									
Profit for the period								8,257	8,257
Other comprehensive income				3,209	3,495	203	6,908		6,908
Total comprehensive income for the period	-	-	-	3,209	3,495	203	6,908	8,257	15,165
Transactions with owners									
Purchase of treasury shares			(0)						(0)
Disposal of treasury shares		(57)	77						20
Dividends								(1,435)	(1,435)
Share-based payment transactions		3	16						20
Transfer to retained earnings				(24)			(24)	24	-
Total	-	(53)	94	(24)	-	-	(24)	(1,411)	(1,394)
Balance at end of the period	6,544	5,988	(4,130)	16,822	31,472	733	49,029	114,515	171,946

	Non-controlling interests	Total
Balance at beginning of the period	2,052	160,228
Comprehensive income		
Profit for the period	123	8,381
Other comprehensive income	(25)	6,882
Total comprehensive income for the period	98	15,263
Transactions with owners		
Purchase of treasury shares		(0)
Disposal of treasury shares		20
Dividends	(184)	(1,620)
Share-based payment transactions		20
Transfer to retained earnings		-
Total	(184)	(1,579)
Balance at end of the period	1,965	173,912

(4) Condensed semi-annual consolidated statement of cash flows

(Millions of yen)

	Six months ended June 30, 2025 (From January 1, 2025 to June 30, 2025)	Six months ended June 30, 2026 (From January 1, 2026 to June 30, 2026)
Cash flows from operating activities		
Profit before tax	4,845	10,396
Depreciation and amortization	5,496	5,802
Impairment losses (Reversal of impairment losses)	(33)	-
Interest and dividend income	(683)	(576)
Interest expenses	564	682
Foreign exchange losses (gains)	1,511	(324)
Share of loss (profit) of associates and joint ventures accounted for using the equity method	(143)	(379)
(Profits) losses on sale and disposal of property, plant and equipment	(167)	(16)
Losses on sales of shares of subsidiaries and associates (gains)	(455)	-
Decrease (increase) in trade and other receivables	949	(3,873)
Decrease (increase) in inventories	(4,198)	(1,163)
Increase (decrease) in trade and other payables	1,531	(1,835)
Increase (decrease) in contract liabilities	(55)	(3,948)
Increase (decrease) in net defined benefit liabilities	(1)	(52)
Other	(1,029)	(6,194)
Subtotal	8,129	(1,484)
Interest and dividends received	687	656
Interest paid	(528)	(695)
Income taxes paid	(1,031)	(1,024)
Income taxes refund	291	460
Net cash provided by operating activities	7,548	(2,088)

	Six months ended June 30, 2025 (From January 1, 2025 to June 30, 2025)	Six months ended June 30, 2026 (From January 1, 2026 to June 30, 2026)
Cash flows from investing activities		
Payments into time deposits	(0)	(3)
Proceeds from withdrawal of time deposits	-	3
Purchase of property, plant and equipment	(2,261)	(3,187)
Proceeds from sale of property, plant and equipment	171	476
Purchase of intangible assets	(303)	(1,001)
Proceeds from sale of equity instruments	167	40
Proceeds from sales of shares of subsidiaries and associates resulting in change in scope of consolidation	5,798	-
Proceeds from sale of businesses	610	-
Payments made for short-term loans receivable	(2)	(1)
Proceeds from collection of short-term loans receivable	2	1
Net cash provided by (used in) investing activities	4,182	(3,671)
Cash flows from financing activities		
Proceeds from short-term borrowings	742	791
Repayments of short-term borrowings	(802)	(791)
Repayments of lease liabilities	(2,021)	(2,262)
Proceeds from long-term borrowings	-	4,977
Repayments of long-term borrowings	(5,089)	(2,559)
Payments for purchase of treasury shares	(0)	(0)
Dividends paid	(993)	(1,435)
Dividends paid to non-controlling interests	(127)	(184)
Net cash provided by (used in) financing activities	(8,292)	(1,465)
Effects of exchange rate changes on the balance of cash and cash equivalents held in foreign currencies	(1,208)	623
Increase (decrease) in cash and cash equivalents	2,230	(6,600)
Cash and cash equivalents at beginning of the period	34,663	44,584
Reversal of cash and cash equivalents included in assets held for sale	1,239	-
Cash and cash equivalents at end of the period	38,133	37,983

(5) Notes to Condensed Semi-Annual Consolidated Financial Statements
(Notes on the Going Concern Assumption)
Not applicable.

(Segment information)

(1) Overview of Reporting Segments

There are no significant changes to the method of identifying reporting segments or the metrics for measuring segment profits in the semi-annual consolidated accounting period.

(2) Segment Revenue and Performance Results

Information by the reportable segment is as follows.

Six Month ended June 30, 2025 (January 1, 2025 to June 30, 2025)

(Millions of yen)

	Reportable Segment			Reconciliations (Note 1)	Per condensed semi- annual consolidated financial statements (Note 2)
	Industrial Unit	Medical Unit	Total		
Revenue					
Revenue from external customers	61,731	38,586	100,317	-	100,317
Intersegment revenue or transfers	116	-	116	(116)	-
Total	61,847	38,586	100,434	(116)	100,317
Segment Profit	4,468	2,592	7,061	(1,194)	5,867
Other items					
Financial income					787
Financial costs					1,952
Share of profit (loss) of associates and joint ventures accounted for using the equity method					143
Profit before tax					4,845

Note: 1. Of the adjustments for segment profit, (1,735) million yen is for company-wide expenses that have not been allocated to each reporting segment, 85 million yen is for the elimination of inter-segment transactions, and 455 million yen is for gains on the sale of shares of affiliated companies. Corporate expenses are primarily general and administrative expenses that are not attributable to the Reporting segment.

2. Segment profit is adjusted to operating profit as presented in the condensed semi-annual consolidated statement of profit or loss.

Six Month ended June 30, 2026 (January 1, 2026 to June 30, 2026)

(Millions of yen)

	Reportable segment			Reconciliations (Note 1)	Per condensed semi- annual consolidated financial statements (Note 2)
	Industrial Unit	Medical Unit	Total		
Revenue					
Revenue from external customers	78,074	40,341	118,415	-	118,415
Intersegment revenue or transfers	14	5	19	(19)	-
Total	78,088	40,346	118,434	(19)	118,415
Segment Profit	7,317	3,524	10,841	(1,819)	9,022
Other items					
Financial income					1,682
Financial costs					688
Share of profit (loss) of associates and joint ventures accounted for using the equity method					379
Profit before tax					10,396

Note: 1. Of the adjusted segment profits, (1,919) million yen is for company-wide expenses that have not been allocated to each reporting segment, and 100 million yen is for inter-segment transactions. Corporate expenses are primarily general and administrative expenses that are not attributable to the Reporting segment.

2. Segment profit is adjusted to operating profit as presented in the condensed semi-annual consolidated statement of profit or loss.